Herein, Guoying Ni et al. demonstrated that administering caerin 1.1/1.9 peptide intratumorally, in combination with E7 antigen-specific immunotherapy and IL-10 and PD-1 blockade, improved the TC-1 tumor microenvironment (TME) and increased the efficacy of anti-PD-1 treatment in TC-1 tumor-bearing mice. Here, IL10 is linked to neoplasm.